Opus Genetics, Inc.
IRD- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001228627
In the last 90 days, Opus Genetics, Inc. insiders filed 0 open-market purchases and 5 sales; 103 institutions reported holding it in 13F filings for Q2 2026, worth $249.2M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $213.8K in total
- 5
- 13F holdersQ2 2026, +24 vs. previous quarter
- 103
- 13F valueReported value at the end of Q2 2026
- $249.2M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding IRD, Q2 2026
No superinvestor reported holding IRD at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Opus Genetics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 8, 2026 (view filing)4:05 PM ET | Sep 3 | 5 days | Gagnon Robert E.Chief Financial Officer | SSale | −28.0K | $4.54 | −$127.2K | −4.8%556.4K after | |
| Jul 27, 2026 (view filing)4:08 PM ET | Jul 23 | 4 days | Yerxa Benjamin RPresident | SSale | −7.43K | $2.97 | −$22.1K | −1.0%704.1K after | |
| Jul 27, 2026 (view filing)4:07 PM ET | Jul 23 | 4 days | Schachle Joseph KChief Operating Officer | SSale | −4.64K | $2.94 | −$13.7K | −1.6%291.4K after | |
| Jul 27, 2026 (view filing)4:07 PM ET | Jul 23 | 4 days | Magrath GeorgeChief Executive Officer | SSale | −9.47K | $2.95 | −$27.9K | −0.5%1.73M after | |
| Jul 27, 2026 (view filing)4:06 PM ET | Jul 23 | 4 days | Gagnon Robert E.Chief Financial Officer | SSale | −7.78K | $2.95 | −$22.9K | −1.3%584.4K after | |
| May 20, 2026 (view filing)7:29 PM ET | May 18 | 2 days | Foundation Fighting Blindness Retinal Degeneration Fund and 1 otherDirector, Other: See Remarks | SSale | −1.70M | $4.35 | −$7.39M | −31.0%3.79M after | |
| Apr 27, 2026 (view filing) | Apr 23 | 4 days | Yerxa Benjamin RPresident | SSale | −7.47K | $5.24 | −$39.1K | −1.0%711.5K after | |
| Apr 27, 2026 (view filing) | Apr 23 | 4 days | Schachle Joseph KChief Operating Officer | SSale | −4.70K | $5.22 | −$24.5K | −1.6%296.1K after | |
| Apr 27, 2026 (view filing) | Apr 23 | 4 days | Zaremba Rabourn AmyHead of Fin. Quality Assurance | SSale | −1.64K | $5.20 | −$8.53K | −0.9%188.7K after | |
| Apr 27, 2026 (view filing) | Apr 23 | 4 days | Magrath GeorgeChief Executive Officer | SSale | −9.51K | $5.22 | −$49.6K | −0.5%1.74M after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Opus Genetics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Nantahala Capital Management, LLC | 6,122,718 | $25.2M | 0.76% | +4,441,388+264.2% | Added |
| Caligan Partners LP | 6,077,084 | $25.0M | 1.21% | +2,0560.0% | Added |
| Adage Capital Partners GP, L.L.C. | 6,029,775 | $24.8M | 0.03% | 00.0% | Unchanged |
| BIOS Capital Management, LP | 3,683,429 | $15.1M | 36.33% | 00.0% | Unchanged |
| BlackRock, Inc. | 3,116,487 | $12.8M | 0.00% | +2,968,747+2,009.4% | Added |
| Balyasny Asset Management LLC | 3,087,866 | $12.7M | 0.02% | +369,837+13.6% | Added |
| Vanguard Capital Management LLC | 2,958,683 | $12.2M | 0.00% | +508,696+20.8% | Added |
| Boxer Capital Management, LLC | 2,815,000 | $11.6M | 0.87% | +565,000+25.1% | Added |
| Trails Edge Capital Partners, LP | 2,743,658 | $11.3M | 1.79% | +2,243,658+448.7% | Added |
| Millennium Management LLC | 2,302,101 | $9.46M | 0.01% | −328,331−12.5% | Reduced |